New Risk • Aug 12
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 12% Last year net profit margin: 20% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (12% net profit margin). 공고 • Aug 05
Fermenta Biotech Limited to Report Q1, 2027 Results on Aug 11, 2026 Fermenta Biotech Limited announced that they will report Q1, 2027 results on Aug 11, 2026 Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹466, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 205% over the past three years. Upcoming Dividend • Jul 29
Upcoming dividend of ₹3.75 per share Eligible shareholders must have bought the stock before 05 August 2026. Payment date: 21 August 2026. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.4%). In line with average of industry peers (0.7%). Reported Earnings • Jul 22
Full year 2026 earnings released: EPS: ₹24.70 (vs ₹26.35 in FY 2025) Full year 2026 results: EPS: ₹24.70 (down from ₹26.35 in FY 2025). Revenue: ₹5.25b (up 12% from FY 2025). Net income: ₹717.7m (down 6.6% from FY 2025). Profit margin: 14% (down from 16% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. New Risk • Jul 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.6% average weekly change). Valuation Update With 7 Day Price Move • Jul 10
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹412, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 200% over the past three years. Declared Dividend • May 29
Dividend increased to ₹3.75 Dividend of ₹3.75 is 50% higher than last year. Ex-date: 5th August 2026 Payment date: 21st August 2026 Dividend yield will be 1.3%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (9% earnings payout ratio) and cash flows (12% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 9.1% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. 공고 • May 28
Fermenta Biotech Limited announces Annual dividend, payable on August 21, 2026 Fermenta Biotech Limited announced Annual dividend of INR 3.7500 per share payable on August 21, 2026, ex-date on August 05, 2026 and record date on August 05, 2026. 공고 • May 27
Fermenta Biotech Limited, Annual General Meeting, Aug 11, 2026 Fermenta Biotech Limited, Annual General Meeting, Aug 11, 2026. Reported Earnings • May 27
Full year 2026 earnings released: EPS: ₹24.70 (vs ₹26.35 in FY 2025) Full year 2026 results: EPS: ₹24.70 (down from ₹26.35 in FY 2025). Revenue: ₹5.48b (up 17% from FY 2025). Net income: ₹717.7m (down 6.6% from FY 2025). Profit margin: 13% (down from 16% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • May 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.3% to ₹299. The fair value is estimated to be ₹379, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Mar 30
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹9.39b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹9.39b market cap, or US$99.2m). Reported Earnings • Feb 10
Third quarter 2026 earnings released: EPS: ₹4.36 (vs ₹12.71 in 3Q 2025) Third quarter 2026 results: EPS: ₹4.36 (down from ₹12.71 in 3Q 2025). Revenue: ₹1.40b (down 10% from 3Q 2025). Net income: ₹126.8m (down 66% from 3Q 2025). Profit margin: 9.0% (down from 24% in 3Q 2025). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. New Risk • Jan 23
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹9.16b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹9.16b market cap, or US$99.8m). New Risk • Dec 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (6.9% average weekly change). Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹320, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 82% over the past three years. Reported Earnings • Nov 12
Second quarter 2026 earnings released: EPS: ₹6.48 (vs ₹3.94 in 2Q 2025) Second quarter 2026 results: EPS: ₹6.48 (up from ₹3.94 in 2Q 2025). Revenue: ₹1.36b (up 43% from 2Q 2025). Net income: ₹188.8m (up 66% from 2Q 2025). Profit margin: 14% (up from 12% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. New Risk • Oct 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.80b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₹8.80b market cap, or US$99.1m). Upcoming Dividend • Jul 30
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 06 August 2025. Payment date: 22 August 2025. Payout ratio is a comfortable 9.5% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.2%). In line with average of industry peers (0.7%). Reported Earnings • Jul 23
Full year 2025 earnings released: EPS: ₹26.35 (vs ₹7.99 loss in FY 2024) Full year 2025 results: EPS: ₹26.35 (up from ₹7.99 loss in FY 2024). Revenue: ₹4.69b (up 40% from FY 2024). Net income: ₹768.6m (up ₹999.2m from FY 2024). Profit margin: 16% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹384, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 107% over the past three years. Declared Dividend • May 31
Dividend increased to ₹2.50 Dividend of ₹2.50 is 100% higher than last year. Ex-date: 6th August 2025 Payment date: 22nd August 2025 Dividend yield will be 0.8%, which is about the same as the industry average. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (20% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years. However, payments have been volatile during that time. Reported Earnings • May 29
Full year 2025 earnings released: EPS: ₹26.35 (vs ₹7.99 loss in FY 2024) Full year 2025 results: EPS: ₹26.35 (up from ₹7.99 loss in FY 2024). Revenue: ₹4.81b (up 43% from FY 2024). Net income: ₹768.6m (up ₹999.2m from FY 2024). Profit margin: 16% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. 공고 • May 21
Fermenta Biotech Limited to Report Q4, 2025 Results on May 28, 2025 Fermenta Biotech Limited announced that they will report Q4, 2025 results at 9:15 AM, Indian Standard Time on May 28, 2025 Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹303, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹294, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 42% over the past three years. Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹267, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹279, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 13% over the past three years. New Risk • Feb 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.47b (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 54% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Significant insider selling over the past 3 months (₹26m sold). Market cap is less than US$100m (₹8.47b market cap, or US$97.5m). Reported Earnings • Feb 13
Third quarter 2025 earnings released: EPS: ₹12.71 (vs ₹3.41 in 3Q 2024) Third quarter 2025 results: EPS: ₹12.71 (up from ₹3.41 in 3Q 2024). Revenue: ₹1.56b (up 58% from 3Q 2024). Net income: ₹369.1m (up 275% from 3Q 2024). Profit margin: 24% (up from 10.0% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. New Risk • Feb 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 65% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹26m sold). 공고 • Feb 04
Fermenta Biotech Limited to Report Q3, 2025 Results on Feb 11, 2025 Fermenta Biotech Limited announced that they will report Q3, 2025 results on Feb 11, 2025 New Risk • Dec 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (7.7% average weekly change). Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹26m sold). Recent Insider Transactions • Nov 28
MD & Additional Director recently sold ₹22m worth of stock On the 25th of November, Prashant Nagre sold around 67k shares on-market at roughly ₹328 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Prashant's only on-market trade for the last 12 months. Reported Earnings • Nov 15
Second quarter 2025 earnings released: EPS: ₹3.94 (vs ₹9.63 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹3.94 (up from ₹9.63 loss in 2Q 2024). Revenue: ₹979.1m (up 72% from 2Q 2024). Net income: ₹113.8m (up ₹391.8m from 2Q 2024). Profit margin: 12% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. 공고 • Nov 08
Fermenta Biotech Limited to Report Q2, 2025 Results on Nov 14, 2024 Fermenta Biotech Limited announced that they will report Q2, 2025 results on Nov 14, 2024 New Risk • Aug 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₹7.72b market cap, or US$92.1m). 공고 • Aug 06
Fermenta Biotech Limited to Report Q1, 2025 Results on Aug 12, 2024 Fermenta Biotech Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Upcoming Dividend • Jul 30
Upcoming dividend of ₹1.25 per share Eligible shareholders must have bought the stock before 06 August 2024. Payment date: 22 August 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.7%). Reported Earnings • Jul 25
Full year 2024 earnings released: ₹7.99 loss per share (vs ₹17.70 loss in FY 2023) Full year 2024 results: ₹7.99 loss per share (improved from ₹17.70 loss in FY 2023). Revenue: ₹3.36b (down 4.1% from FY 2023). Net loss: ₹230.6m (loss narrowed 55% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. 공고 • Jul 24
Fermenta Biotech Limited Announces Company Secretary Changes Fermenta Biotech Limited informed that Mr. Srikant N. Sharma, Company Secretary (Key Managerial Personnel) [Membership No. FCS-3617], has retired as Company Secretary (Key Managerial Personnel) of the Company from the end of the day on July 23, 2024, and Mr. Varadvinayak Vijay Khambete [Membership No. ACS-33861] is appointed as the Company Secretary (Key Managerial Personnel) of the Company effective July 24, 2024. 공고 • May 19
Fermenta Biotech Limited to Report Q4, 2024 Results on May 27, 2024 Fermenta Biotech Limited announced that they will report Q4, 2024 results on May 27, 2024 Board Change • May 01
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Pramod Kasat was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 13
Third quarter 2024 earnings released: EPS: ₹3.41 (vs ₹12.97 loss in 3Q 2023) Third quarter 2024 results: EPS: ₹3.41 (up from ₹12.97 loss in 3Q 2023). Revenue: ₹1.01b (up 85% from 3Q 2023). Net income: ₹98.5m (up ₹472.4m from 3Q 2023). Profit margin: 9.7% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 09
Second quarter 2024 earnings released: ₹9.63 loss per share (vs ₹2.79 loss in 2Q 2023) Second quarter 2024 results: ₹9.63 loss per share (further deteriorated from ₹2.79 loss in 2Q 2023). Revenue: ₹588.0m (down 42% from 2Q 2023). Net loss: ₹278.0m (loss widened 245% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance. 공고 • Oct 31
Fermenta Biotech Limited to Report Q2, 2024 Results on Nov 08, 2023 Fermenta Biotech Limited announced that they will report Q2, 2024 results on Nov 08, 2023 공고 • Oct 01
Fermenta Biotech Limited Approves Dividend for the Financial Year Ended March 31, 2023, Payable on or Before October 10, 2023 Fermenta Biotech Limited announced that at its AGM held on September 29, 2023 declared dividend of INR 1.25 per equity share of INR 5 each for the financial year ended March 31, 2023. The dividend will be paid to the shareholders of the Company on or before October 10, 2023 to those shareholders /beneficial owners whose names appear in the Register of Members as on Record Date, September 22, 2023. 공고 • Aug 12
Fermenta Biotech Limited, Annual General Meeting, Sep 29, 2023 Fermenta Biotech Limited, Annual General Meeting, Sep 29, 2023. 공고 • Aug 03
Fermenta Biotech Limited to Report Q1, 2024 Results on Aug 11, 2023 Fermenta Biotech Limited announced that they will report Q1, 2024 results on Aug 11, 2023 공고 • Jul 12
Fermenta Biotech Limited Announces Suspension of Operations Due to Heavy Rainfall in Himachal Pradesh Fermenta Biotech Limited announced that in view of the natural calamity i.e. heavy rainfall in Himachal Pradesh, the operations at Company's facility situated at Kullu, Himachal Pradesh, India are stopped completely since July 10, 2023. The details required to be submitted under SEBI circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015 ("Circular") are as follows: Expected quantum of loss/damage caused: The Company is in the process of ascertaining the quantum of loss/damage caused by the above disruption. In terms of the Circular, the Company will report the details including steps taken to restore its operations, the damage caused, insurance amount realized and the commencement of operations at Kullu factory, in due course. 공고 • May 30
Fermenta Biotech Limited Recommends Final Equity Dividend for the Financial Year Ended March 31, 2023 Fermenta Biotech Limited recommended final equity dividend @ INR 1.25/- per equity share (25%) of INR 5/- each for the financial year ended March 31, 2023 for members' approval. (Date of dispatch/payment of the aforesaid final equity dividend shall be announced separately once the Annual General Meeting date is decided by the Board of Directors). Reported Earnings • May 30
Full year 2023 earnings released: ₹17.85 loss per share (vs ₹5.36 profit in FY 2022) Full year 2023 results: ₹17.85 loss per share (down from ₹5.36 profit in FY 2022). Revenue: ₹3.58b (down 10% from FY 2022). Net loss: ₹515.0m (down 433% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. 공고 • May 23
Fermenta Biotech Limited to Report Q4, 2023 Results on May 29, 2023 Fermenta Biotech Limited announced that they will report Q4, 2023 results on May 29, 2023 Reported Earnings • Feb 15
Third quarter 2023 earnings released: ₹12.97 loss per share (vs ₹2.79 loss in 3Q 2022) Third quarter 2023 results: ₹12.97 loss per share (further deteriorated from ₹2.79 loss in 3Q 2022). Revenue: ₹548.6m (down 41% from 3Q 2022). Net loss: ₹373.9m (loss widened 365% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. 공고 • Jan 18
Red Brick It Support Services LLP acquired premises in Thane One Building from Fermenta Biotech Limited (BSE:506414) for Rs 138.85 million. Red Brick It Support Services LLP acquired premises in Thane One Building from Fermenta Biotech Limited (BSE:506414) for Rs 138.85 million on January 17, 2023.Red Brick It Support Services LLP completed the acquisition of premises in Thane One Building from Fermenta Biotech Limited (BSE:506414) for Rs 138.85 million on January 17, 2023. Reported Earnings • Nov 20
Second quarter 2023 earnings released: ₹2.79 loss per share (vs ₹1.56 profit in 2Q 2022) Second quarter 2023 results: ₹2.79 loss per share (down from ₹1.56 profit in 2Q 2022). Revenue: ₹1.01b (flat on 2Q 2022). Net loss: ₹80.5m (down 279% from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Non-Executive Independent Director Rajashri Santosh Ojha was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Nov 03
Fermenta Biotech Limited to Report Q2, 2023 Results on Nov 11, 2022 Fermenta Biotech Limited announced that they will report Q2, 2023 results on Nov 11, 2022 Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment improved over the past week After last week's 16% share price gain to ₹206, the stock trades at a trailing P/E ratio of 38.5x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 28% over the past three years. 공고 • Aug 06
Fermenta Biotech Limited to Report Q1, 2023 Results on Aug 12, 2022 Fermenta Biotech Limited announced that they will report Q1, 2023 results on Aug 12, 2022 Upcoming Dividend • Jul 28
Upcoming dividend of ₹1.25 per share Eligible shareholders must have bought the stock before 04 August 2022. Payment date: 22 August 2022. Payout ratio is a comfortable 23% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (1.0%). Reported Earnings • Jul 19
Full year 2022 earnings released: EPS: ₹5.36 (vs ₹15.78 in FY 2021) Full year 2022 results: EPS: ₹5.36 (down from ₹15.78 in FY 2021). Revenue: ₹3.99b (up 5.6% from FY 2021). Net income: ₹154.5m (down 66% from FY 2021). Profit margin: 3.9% (down from 12% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. 공고 • Jul 17
Fermenta Biotech Limited, Annual General Meeting, Aug 12, 2022 Fermenta Biotech Limited, Annual General Meeting, Aug 12, 2022, at 16:00 Indian Standard Time. Agenda: To receive, consider and adopt: the audited Standalone Financial Statements of the Company for the financial year ended March 31, 2022, Reports of the Board of Directors, and the Auditors thereon; and the audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2022, and the Report of the Auditors thereon; to declare dividend for the financial year ended March 31, 2022; to consider board changes; to appoint Statutory Auditors and fix their remuneration; to consider the remuneration of Cost Auditor of the Company; and to approve Material Related Party Transaction. Reported Earnings • Jun 04
Full year 2022 earnings released: EPS: ₹5.36 (vs ₹15.78 in FY 2021) Full year 2022 results: EPS: ₹5.36 (down from ₹15.78 in FY 2021). Revenue: ₹3.99b (up 5.6% from FY 2021). Net income: ₹154.5m (down 66% from FY 2021). Profit margin: 3.9% (down from 12% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. 공고 • May 31
Fermenta Biotech Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022, Payable on or Before August 22, 2022 Fermenta Biotech Limited Recommended final equity dividend at INR 1.25 per equity share (25%) of INR 5 each for the financial year ended March 31, 2022 if declared at the AGM of the Company on August 12, 2022, will be paid to the shareholders of the Company on or before August 22, 2022 to those shareholders /beneficial owners whose names appear in the Register of Members as on August 5, 2022. 공고 • May 24
Fermenta Biotech Limited to Report Q4, 2022 Results on May 30, 2022 Fermenta Biotech Limited announced that they will report Q4, 2022 results on May 30, 2022 Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Executive Independent Director Rajashri Santosh Ojha was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improved over the past week After last week's 20% share price gain to ₹246, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total loss to shareholders of 9.9% over the past three years. Reported Earnings • Feb 15
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: ₹2.79 loss per share (down from ₹3.40 profit in 3Q 2021). Revenue: ₹940.3m (up 4.5% from 3Q 2021). Net loss: ₹80.4m (down 182% from profit in 3Q 2021). Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 26%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. 공고 • Feb 05
Fermenta Biotech Limited to Report Q3, 2022 Results on Feb 14, 2022 Fermenta Biotech Limited announced that they will report Q3, 2022 results on Feb 14, 2022 Board Change • Jan 05
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Non-Executive Independent Director Rajashri Santosh Ojha was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Oct 08
Investor sentiment improved over the past week After last week's 15% share price gain to ₹309, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 25% over the past three years. Upcoming Dividend • Aug 18
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 25 August 2021. Payment date: 13 September 2021. Trailing yield: 0.9%. Lower than top quartile of Indian dividend payers (1.5%). In line with average of industry peers (0.8%). Reported Earnings • Aug 15
Full year 2021 earnings released: EPS ₹15.78 (vs ₹20.64 in FY 2020) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: ₹3.77b (up 29% from FY 2020). Net income: ₹455.1m (down 24% from FY 2020). Profit margin: 12% (down from 20% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Reported Earnings • Jul 03
Full year 2021 earnings released: EPS ₹15.78 (vs ₹20.64 in FY 2020) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: ₹3.77b (up 29% from FY 2020). Net income: ₹455.1m (down 24% from FY 2020). Profit margin: 12% (down from 20% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improved over the past week After last week's 17% share price gain to ₹302, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 20% over the past three years. Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS ₹3.40 (vs ₹3.35 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₹906.8m (up 30% from 3Q 2020). Net income: ₹98.0m (up 1.5% from 3Q 2020). Profit margin: 11% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 3% per year. Is New 90 Day High Low • Feb 11
New 90-day low: ₹283 The company is down 14% from its price of ₹329 on 13 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. 공고 • Feb 04
Fermenta Biotech Limited to Report Q3, 2021 Results on Feb 11, 2021 Fermenta Biotech Limited announced that they will report Q3, 2021 results on Feb 11, 2021 Is New 90 Day High Low • Jan 22
New 90-day low: ₹291 The company is down 14% from its price of ₹337 on 23 October 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Valuation Update With 7 Day Price Move • Dec 09
Market bids up stock over the past week After last week's 16% share price gain to ₹357, the stock is trading at a trailing P/E ratio of 25.1x, up from the previous P/E ratio of 21.6x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 181%. Valuation Update With 7 Day Price Move • Nov 17
Market bids up stock over the past week After last week's 16% share price gain to ₹340, the stock is trading at a trailing P/E ratio of 23.8x, up from the previous P/E ratio of 20.6x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 201%. Reported Earnings • Nov 10
Second quarter 2021 earnings released: EPS ₹5.10 The company reported a soft second quarter result with weaker earnings and profit margins, although revenues were improved. Second quarter 2021 results: Revenue: ₹950.3m (up 18% from 2Q 2020). Net income: ₹147.1m (down 55% from 2Q 2020). Profit margin: 16% (down from 41% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Nov 02
New 90-day low: ₹297 The company is down 12% from its price of ₹339 on 04 August 2020. The Indian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. 공고 • Sep 09
Fermenta Biotech Limited to Report Q1, 2021 Results on Sep 14, 2020 Fermenta Biotech Limited announced that they will report Q1, 2021 results on Sep 14, 2020 공고 • Aug 26
Fermenta Biotech Limited to Report Fiscal Year 2020 Results on Aug 28, 2020 Fermenta Biotech Limited announced that they will report fiscal year 2020 results on Aug 28, 2020 공고 • Jun 20
Fermenta Biotech Limited to Report Q4, 2020 Results on Jun 29, 2020 Fermenta Biotech Limited announced that they will report Q4, 2020 results on Jun 29, 2020 
